Australia markets closed

ABBV Jun 2024 230.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.00000.0000 (0.00%)
As of 02:40PM EST. Market open.
Full screen
Previous close3.0000
Expiry date2024-06-21
Day's range3.0000 - 3.0500
Contract rangeN/A
Open interestN/A
  • Motley Fool

    Is AbbVie Stock a Buy Now?

    Given the volatility of AbbVie's (NYSE: ABBV) stock over the past year, it's pretty clear that traders are worried about next year's impending Humira patent cliff. Although the way AbbVie is going, an earnings slump is likely to be short-lived. Humira was seen as a blockbuster from the beginning; the rheumatoid arthritis medication brought in $800 million in its first full year of sales in 2003, back when AbbVie was still part of Abbott Laboratories.

  • PR Newswire

    AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress

    AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation Congress 2022 (EHC 2022) taking place in Vienna, Austria, December 7-10. A total of 15 abstracts will cover a wide range of studies across AbbVie's migraine portfolio, including data on onabotulinumtoxinA and atogepant.

  • Zacks

    Relative Strength Found Within These 3 Medical Stocks

    The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.